Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2003336 | 0.91 | RIPK1 (0.39) | NAMPTGAAL3MBTL1FFAR4SCN5A | |
| SCHEMBL2011222 | 0.79 | GPBAR1 (0.40) | LMNAROCK2ROCK1FFAR4SCN5A | |
| SCHEMBL15336756 | 0.78 | TSHR (0.58) | GAALMNATSHRALDH1A1 | |
| SCHEMBL24838807 | 0.75 | ALDH1A1 (0.51) | L3MBTL1TSHRALDH1A1 | |
| SCHEMBL10165058 | 0.75 | ALDH1A1 (0.51) | ROCK2ROCK1ALDH1A1 | |
| SCHEMBL2574214 | 0.74 | CYP1A2 (0.56) | TSHRALDH1A1 | |
| SCHEMBL8232973 | 0.73 | ALDH1A1 (0.56) | LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL5718761 | 0.73 | ALDH1A1 (0.51) | NAMPTL3MBTL1TSHRALDH1A1 | |
| SCHEMBL12231328 | 0.73 | ALDH1A1 (0.51) | NAMPTL3MBTL1TSHRALDH1A1 | |
| SCHEMBL2948042 | 0.72 | ALDH1A1 (0.50) | L3MBTL1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960365-B2 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2011-06-14 | — | — | US | disclosed |
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | NR3C1, NR3C2, MC2R | NAMPT 4461/4885GAA 3832/4885LMNA 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.